Anny Fis

  • NanoTemper Technologies announces Dianthus α, an applications package, to push the boundaries of in-solution binding analysis.  

    NanoTemper Technologies announces Dianthus α, an applications package, to push the boundaries of in-solution binding analysis.  

    Drug discovery teams need high-confidence data to accelerate hit-to-lead workflows and take on targets once considered undruggable.

    Read
  • 10 Evolved Terms Every Scientist Should Know About Targeted Protein Degradation in 2025

    10 Evolved Terms Every Scientist Should Know About Targeted Protein Degradation in 2025

    Explore 10 advanced concepts redefining targeted protein degradation in 2025, including AI-guided design, novel degrader modalities, and tissue-specific E3 ligases for scientists working on TPD

    Read
  • Ultra-high-throughput biophysical screening of MEK1 using the Dianthus uHTS platform

    Ultra-high-throughput biophysical screening of MEK1 using the Dianthus uHTS platform

    Read
  • Pushing Boundaries in Biophysics and Biomanufacturing

    Pushing Boundaries in Biophysics and Biomanufacturing

    Marius, a biophysics expert at Johnson & Johnson Innovative Medicine, shares his insights into this rapidly evolving field of biomanufacturing.

    Read
  • NanoTemper Announces Leadership Evolution: Philipp Baaske Transitions to Executive Chairman

    NanoTemper Announces Leadership Evolution: Philipp Baaske Transitions to Executive Chairman

    NanoTemper Technologies is entering a new chapter of leadership. After 16 years as Co-CEOs, Philipp Baaske and Stefan Duhr have redefined their roles to better position the company for continued growt

    Read
  • loading
    Loading more...